336 related articles for article (PubMed ID: 11772881)
1. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.
Esposito G; Rapacciuolo A; Naga Prasad SV; Takaoka H; Thomas SA; Koch WJ; Rockman HA
Circulation; 2002 Jan; 105(1):85-92. PubMed ID: 11772881
[TBL] [Abstract][Full Text] [Related]
2. Still stressed out but doing fine: normalization of wall stress is superfluous to maintaining cardiac function in chronic pressure overload.
Sano M; Schneider MD
Circulation; 2002 Jan; 105(1):8-10. PubMed ID: 11772868
[No Abstract] [Full Text] [Related]
3. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload.
Esposito G; Prasad SV; Rapacciuolo A; Mao L; Koch WJ; Rockman HA
Circulation; 2001 Mar; 103(10):1453-8. PubMed ID: 11245652
[TBL] [Abstract][Full Text] [Related]
4. Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy.
Shi J; Zhang YW; Summers LJ; Dorn GW; Wei L
J Mol Cell Cardiol; 2008 Mar; 44(3):551-60. PubMed ID: 18178218
[TBL] [Abstract][Full Text] [Related]
5. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.
Perrino C; Naga Prasad SV; Mao L; Noma T; Yan Z; Kim HS; Smithies O; Rockman HA
J Clin Invest; 2006 Jun; 116(6):1547-60. PubMed ID: 16741575
[TBL] [Abstract][Full Text] [Related]
6. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy.
Rapacciuolo A; Esposito G; Caron K; Mao L; Thomas SA; Rockman HA
J Am Coll Cardiol; 2001 Sep; 38(3):876-82. PubMed ID: 11527648
[TBL] [Abstract][Full Text] [Related]
7. Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature.
Keys JR; Greene EA; Koch WJ; Eckhart AD
Hypertension; 2002 Nov; 40(5):660-6. PubMed ID: 12411459
[TBL] [Abstract][Full Text] [Related]
8. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure.
Tachibana H; Naga Prasad SV; Lefkowitz RJ; Koch WJ; Rockman HA
Circulation; 2005 Feb; 111(5):591-7. PubMed ID: 15668342
[TBL] [Abstract][Full Text] [Related]
9. CCN2/CTGF attenuates myocardial hypertrophy and cardiac dysfunction upon chronic pressure-overload.
Gravning J; Ahmed MS; von Lueder TG; Edvardsen T; Attramadal H
Int J Cardiol; 2013 Oct; 168(3):2049-56. PubMed ID: 23452880
[TBL] [Abstract][Full Text] [Related]
10. Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy.
Manning BS; Shotwell K; Mao L; Rockman HA; Koch WJ
Circulation; 2000 Nov; 102(22):2751-7. PubMed ID: 11094043
[TBL] [Abstract][Full Text] [Related]
11. The valosin-containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload.
Zhou N; Ma B; Stoll S; Hays TT; Qiu H
Aging Cell; 2017 Oct; 16(5):1168-1179. PubMed ID: 28799247
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of impaired beta-adrenergic receptor signaling in G(alphaq)-mediated cardiac hypertrophy and ventricular dysfunction.
Dorn GW; Tepe NM; Wu G; Yatani A; Liggett SB
Mol Pharmacol; 2000 Feb; 57(2):278-87. PubMed ID: 10648637
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase.
Choi DJ; Koch WJ; Hunter JJ; Rockman HA
J Biol Chem; 1997 Jul; 272(27):17223-9. PubMed ID: 9202046
[TBL] [Abstract][Full Text] [Related]
14. Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice.
Dorn GW; Tepe NM; Lorenz JN; Koch WJ; Liggett SB
Proc Natl Acad Sci U S A; 1999 May; 96(11):6400-5. PubMed ID: 10339599
[TBL] [Abstract][Full Text] [Related]
15. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice.
Sakata Y; Hoit BD; Liggett SB; Walsh RA; Dorn GW
Circulation; 1998 Apr; 97(15):1488-95. PubMed ID: 9576430
[TBL] [Abstract][Full Text] [Related]
16. Sympathetic alpha(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload.
Gilsbach R; Schneider J; Lother A; Schickinger S; Leemhuis J; Hein L
Cardiovasc Res; 2010 Jun; 86(3):432-42. PubMed ID: 20083574
[TBL] [Abstract][Full Text] [Related]
17. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload.
Zhou H; Bian ZY; Zong J; Deng W; Yan L; Shen DF; Guo H; Dai J; Yuan Y; Zhang R; Lin YF; Hu X; Li H; Tang QZ
Hypertension; 2012 Sep; 60(3):802-9. PubMed ID: 22851736
[TBL] [Abstract][Full Text] [Related]
18. The contributions of cardiac myosin binding protein C and troponin I phosphorylation to β-adrenergic enhancement of in vivo cardiac function.
Gresham KS; Stelzer JE
J Physiol; 2016 Feb; 594(3):669-86. PubMed ID: 26635197
[TBL] [Abstract][Full Text] [Related]
19. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes.
Wettschureck N; Rütten H; Zywietz A; Gehring D; Wilkie TM; Chen J; Chien KR; Offermanns S
Nat Med; 2001 Nov; 7(11):1236-40. PubMed ID: 11689889
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial reprogramming induced by CaMKIIδ mediates hypertrophy decompensation.
Westenbrink BD; Ling H; Divakaruni AS; Gray CB; Zambon AC; Dalton ND; Peterson KL; Gu Y; Matkovich SJ; Murphy AN; Miyamoto S; Dorn GW; Heller Brown J
Circ Res; 2015 Feb; 116(5):e28-39. PubMed ID: 25605649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
